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1. Introduction 
Familial hypercholesterolemia (type IIa hyperlipo- 
proteinemia) is a lipid transport disorder characterized 
by increased concentrations of plasma cholesterol and 
fl-lipoproteins [ 1,2]. This type of hyperlipoproteinemia 
is often accompanied by xanthomatosis and premature 
coronary atherosclerosis [3]. Although several reports 
indicate that LDL* from hypercholesterolemic patients 
have normal hydrated densities and chemical composi- 
tion [s-7], results of other studies show that LDL 
from type II hyperlipoproteinemic subjects differ in 
these parameters from normals [8,9]. Grant et al. [lo] 
reported that water of hydration was significantly 
higher in LDL of a homozygote patient with hyper- 
cholesterolemia than in those of heterozygotes and 
normals, Agostini et al. [ 111 observed that under an 
electron microscope LDL of type II patients tended 
to form elongated or branched stacks, while LDL of 
normal subjects showed spherical shape. 
In an attempt to resolve some of these differences, 
we have initiated a comparative study of the chemistry 
of LDL from normal [ 121 and hypercholesterolemic 
subjects. Here we present the identification of apolipo- 
proteins and their polypeptides in each major lipopro- 
tein density class in the plasma of patients with type 
IIa hyperlipoproteinemia. We found a great similarity 
* Abbreviations.. VLDL, very low density lipoproteins, 
lipoproteins of d < 1.006 g/ml; LDL, low density lipo. 
proteins, lipoproteins of d 1.006-1.063 g/ml; HDL, 
high density lipoproteins, lipoproteins of d 1.063-1.21 
g/ml. Lipoprotein families and apolipoproteins were 
designated according to the ABC’ nomenclature [4]. 
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in the polypeptide patterns of VLDL and LDL sub- 
fractions in the plasma of normal and type IIa hyper- 
lipoproteinemic subjects. Minor differences were 
noted in the HDL subfractions. 
2. Materials and methods 
2.1. Isolation of lipoprotein density classes 
Plasma was obtained by plasmapheresis from seven 
type IIa hyperlipoproteinemic donors. All donors were 
off medication for at least six weeks and were fasted 
for 12-14 hr before blood was drawn. Lipoprotein 
density fractions were isolated from individual plasma 
samples. The VLDL and three subfractions of LDL 
(LDLr, d = 1.006-l .019 g/ml, LDLz, d = 1.019- 
1.053 g/ml, and LDLa , d = 1.053-l .063 g/ml) were 
isolated by ultracentrifugation [ 121. To isolate two 
subfractions of HDL (HDLa , d = 1.063- 1.120 g/ml, 
and HDLs, d = 1.120-l .21 g/ml), the plasma of 
d > 1.063 g/ml was adjusted with solid KBr to a 
solution density 1.12 and 1.2 1 g/ml successively, and 
centrifuged at 4.5 000 rev/min for 30 hr. All density 
fractions were recentrifuged until free of albumin as 
tested by double diffusion with antibodies to albumin. 
An LDL sample was subjected to a density gradient 
banding. The 9.6 ml gradient of KBr solution extend- 
ing from 1.006 to 1.093 g/ml was layered on top of 
3.5 ml LDLQ , which was pre-adjusted to a density of 
1.21 g/ml with KBr. The gradients were centrifuged in 
swinging-bucket rotor SW40 at 40 000 rev/min for 
24 hr at 10°C. Fractions were collected from the top 
of the tube with a hypodermic syringe. 
Lipoproteins were dialyzed against several changes 
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of 0.15 M NaCl containing 0.05% EDTA and 0.01 M 
(NH4)2 CO3 before use. 
2.2. Delipidization of lipoproteins 
Lipoproteins were delipidized with ethanol-ether 
and separated into soluble and insoluble apolipo- 
proteins [ 121. 
2.3. Polyacrylamide-gel electrophoresis. 
The delipidized lipoprotein fractions were analyzed 
by electrophoresis on 7% polyacrylamide gel contain- 
ing 8 M urea in basic [ 131 and acidic [ 141 buffers. 
Identification of the peptide bands in separating gels 
has been described previously [ 12,151. 
2.4. Immunochemical methods 
The immunochemical properties of lipoproteins 
and apolipoproteins were studied by double diffusion 
in 1% agarose. Antisera to LP-A; LP-B; LP-C; LP-D 
(‘thin-line’); A-I; A-II; C-I; C-II, and C-III peptides 
were prepared and characterized as previously 
reported [4,16]. An antiserum to LP(a) was kindly 
supplied by Dr K. Walton, University of Birmingham, 
England. This antiserum was monospecific for Lp(a) 
lipoprotein and Lp(a) protein, and gave no reaction 
with LP-B or albumin. Antiserum to ‘arginine-rich 
peptide was supplied by Drs W. McConathy and 
P. Alaupotic of the Lipoprotein Laboratory, Oklahoma 
Medical Research Foundation, Oklahoma City. This 
antiserum gave a precipitin line only with ‘arginine- 
rich’ peptide that was isolated from VLDL according 
to Shelburne and Quarfordt [ 171. 
3. Results and discussion 
Table 1 shows the immunochemical and electro- 
phoretic identification of the intact and delipidized 
lipoproteins. All density fractions were found to be 
heterogeneous with respect to the protein moieties. 
Several peptides which had not been detected in the 
intact lipoproteins became detectable after delipidi- 
zation. These included A-I and LDLa and LDLs ; 
A-II in VLDL, LDLz and LDLa ; and ApoD in LDLr . 
Failure to detect these peptides in intact lipoproteins 
might have been due to their extremely low concen- 
Table 1 
Apolipoproteins and their polypeptides identified in intact and delipidized lipoproteins of density classes 
of type Ha hyperlipoproteinemia 
Density 
fractions 
A-l A-II ApoB C-I C-II C-III ApoD 
‘Arg.-rich’ Lp (al 
peptide protein 
Albumin 
VLDL 
apo VLDL - (+I 
LDL, - 
apo LDL, - (+I 
LDL, - 
apo LDL, •t 
LDL, 
apo LDL, -t 
HDL, + 
apo HDL, + 
HDL, + 
apo HDL, + 
- + 
--f t 
- + 
- + 
+ 
--f + 
- + 
+ t 
+ + 
t t 
+ - 
+ - 
+ + t - + _ _ 
t t t _ t - _ 
t t t _ +(-I - _ 
t + t + (-) t(G) - _ 
t + t t + _ 
t t + t t _ _ 
+ t t t t _ _ 
+ t t t t _ _ 
t + t +(-I + + _ 
+ + t t t + - (+) 
+ t t t - _ _ 
t t + t - (+) _ - (+) 
Note: + Positive in all donors studied. 
- Negative in all donors studied. 
+ c-1 Positive in all except one donor. 
- (+l Negative in all except one donor. 
- f Negative in some donors and trace amounts in others, detectable with antibodies only after the 
immunodiffusion patterns were stained with protein stainings. 
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Fig.1. Basic (a) and acidic (b) polyacrylamide gel electrophoretic patterns of soluble apoIipoproteins in VLDL (V), LDL, (L,), 
LDL, (L,), LDL, CL,). HDL, (H,) and HDL, (II,) of a type Ha hyperlipoproteinemic patient. Identification of polypeptide 
bands: C-I (I), dimer of A-I or unidentified polypeptide (2), A-I (3), A-II (4), ApoD (‘Thin line’) (5), C-II (6), C-III-1 (7), C-III-2 
(8) and C-III-3 (9). 
tration and/or the masking of their antigenic sites. 
As in normal subjects, A-I and A-II were also the 
major peptides in HDLa and HDLa of the type Ha 
hyperlipoproteinemics. ApoB was found in all density 
fractions except HDLa Similarly, the C-I, C-II and 
C-III polypeptides of LP-C family were found in all 
density fractions. The soluble apolipoproteins of each 
density fraction were seen in the basic 7% polyacryl- 
amide gel electrophoresis (fig.la). C-I polypeptide 
was not visible in basic polyacrylamide gel pattern; it 
was seen better in acidic polyacrylamide gel as the 
fastest moving band (fig. 1 b). 
ApoD was found in all fractions except VLDL. In 
our experience, ApoD was never found in intact 
HDL:, isolated centrifugally from over 100 normal 
donors of individual and pooled plasma. However, 
traces could be detected after delipidization of 
normal HDLz 
The ‘arginine-rich’ peptide, originally isolated 
from VLDL of normal subjects [ 17,181, was detected 
in all density fractions of type Ila patients except 
HDL3 (fig.2). In normal subjects, however, it was 
detected immunochemically in all density fractions. 
After delipidization, ‘arginine-rich’ peptide was 
mainly associated with the insoluble apolipoproteins. 
The trace amount present in the soluble apolipo- 
118 
proteins, was detectable by immunology but not 
visible on polyacrylamide gel. 
Lp(a), the ‘polymorphic’ form of LP-B, was found 
only in HDLa (fig.3) of all seven type IIa donors 
studied. According to previous reports [ 19,201, and 
our own observation Lp(a) was not identified in 
HDLa of each normal subject. This observation is 
similar to that reported by Walton et al. [2 11. They 
found that both the concentration and frequency of 
occurrence of Lp(a) were higher in type IIa patients 
than in normal subjects. The Lp(a) lipoprotein which 
correlates closely with angina pectoris has been sug- 
gested as a major risk factor in coronary heart disease 
[22,23]. 
Our study confirmed the report of Gotto et al. 
[24], that ApoB in type IIa hyperlipoproteinemia is 
immunochemically identical to ApoB from normal 
plasma. In addition, all the identified apolipoproteins 
and their polypeptides in type Ila hyperlipoprotein- 
emia are immunochemically and electrophoretically 
identical to those from normal plasma. However, our 
findings in LDL subfractions do not agree with the 
report of Fisher et al. [7] that LDL of type IIa hyper- 
lipoproteinemic patients is immunochemically 
homogeneous. It is possible that due to low titer of 
antibodies, their LDL preparations failed to react with 
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Fig.2. Immunodiffusion pattern of lipoprotein fractions in 
1% agarose gel. Wells in the center contain antibodies to 
‘arginine-rich peptide. A, normal VLDL; B through H, lipo- 
protein fractions of a type Ha hyperhpoproteinemic patient. 
B, VLDL, C, LDL, ; D, LDL,; E, LDL,; F, HDL, ; G, HDL,; 
H, 1.21 infranate. 
antibodies to ApoC. Their LDL did react with anti- 
bodies to HDL and produced a ‘faint line’ of precipi- 
tation which was interpreted by the authors as ApoB 
reaction. Reaction of ApoC or ApoD cannot be 
ruled out, however, since normal HDL are known to 
contain ApoC and ApoD (‘thin line’ polypeptide) [4] 
To eliminate the possibility that the disparity in 
results was due to the difference in isolation pro- 
cedures, we subjected the purified LDLa to density 
Fig.3. Immunodiffusion pattern of lipoprotein fractions of 
type IIa hyperlipoproteinemia. Well in the center contains 
antibodies to Lp(a). Outer wells contain lipoprotein samples. 
A, VLDL; B, LDL,, C. LDL,; D, LDL,; E, HDL,; and F, 
HDL,. 
gradient banding. We tested the recovered lipoproteins 
by double diffusion with antibodies to LP-C and 
LP-D. The results indicated that LDLZ purified by 
density gradient banding still contained LP-C and 
LP-D . 
Results of our study show a striking similarity 
between the polypeptide patterns of VLDL and LDL 
subfractions of normal donors, and patients with 
type Da hyperlipoproteinemia. Minor differences 
were noted in HDL subfractions. These findings 
show that the chemical and physical-chemical differ- 
ences observed between LDL from type IIa hyper- 
lipoproteinemics and normal subjects [8-l I] are not 
caused by the presence or absence of a particular 
apolipoprotein (such as ApoA, ApoB, ApoC, ApoD 
and ‘arginine-rich peptide), or its known constituent 
polypeptides (such as A-I, A-II, C-I, C-II or C-III). 
However, we have not ruled out the possibility that 
these differences may be associated with different 
concentrations of the various polypeptides. Indeed, 
some significant differences have been observed in 
the absolute and relative apolipoprotein concentrations 
of LDL subfractions of normal plasma and plasma of 
type Ila patients. These results will be presented in a 
separate communication. 
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